- Home
- NRIX vs PLAY Comparison
NRIX vs PLAY Comparison
Compare NRIX & PLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- PLAY
- Stock Information
- Founded
- NRIX 2009
- PLAY 1982
- Country
- NRIX United States
- PLAY United States
- Employees
- NRIX N/A
- PLAY N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- PLAY Restaurants
- Sector
- NRIX Health Care
- PLAY Consumer Discretionary
- Exchange
- NRIX Nasdaq
- PLAY Nasdaq
- Market Cap
- NRIX 1.3B
- PLAY 1.3B
- IPO Year
- NRIX 2020
- PLAY 1995
- Fundamental
- Price
- NRIX $21.90
- PLAY $34.12
- Analyst Decision
- NRIX Strong Buy
- PLAY Buy
- Analyst Count
- NRIX 15
- PLAY 8
- Target Price
- NRIX $29.33
- PLAY $65.00
- AVG Volume (30 Days)
- NRIX 1.1M
- PLAY 1.1M
- Earning Date
- NRIX 10-11-2024
- PLAY 12-03-2024
- Dividend Yield
- NRIX N/A
- PLAY N/A
- EPS Growth
- NRIX N/A
- PLAY N/A
- EPS
- NRIX N/A
- PLAY 2.71
- Revenue
- NRIX $56,424,000.00
- PLAY $2,211,100,000.00
- Revenue This Year
- NRIX N/A
- PLAY $0.89
- Revenue Next Year
- NRIX $7.17
- PLAY $6.97
- P/E Ratio
- NRIX N/A
- PLAY $12.61
- Revenue Growth
- NRIX N/A
- PLAY 1.23
- 52 Week Low
- NRIX $5.65
- PLAY $29.31
- 52 Week High
- NRIX $29.56
- PLAY $69.82
- Technical
- Relative Strength Index (RSI)
- NRIX 36.80
- PLAY 39.46
- Support Level
- NRIX $20.65
- PLAY $33.09
- Resistance Level
- NRIX $23.09
- PLAY $43.73
- Average True Range (ATR)
- NRIX 1.52
- PLAY 1.86
- MACD
- NRIX -0.58
- PLAY -0.85
- Stochastic Oscillator
- NRIX 14.03
- PLAY 9.49
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
About PLAY Dave & Buster's Entertainment Inc.
Dave & Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.